Lurbinectedin (PM01183) (C09-0935-974)

InformationLurbinectedin (PM01183) Lurbinectedin (PM01183, PM-1183, LY-01017, Tryptamicidin, Zepsyre, ZEPZELCA), a DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Lurbinectedin inhibits RMG1 and RMG2 cell growth with IC50 of 1.25 nM and 1.16 nM, respectively.TargetsDNA minor groove ; RMG2 cell growth (Cell-based assay); RMG1 cell growth (Cell-based assay) ; 1.16 nM ;1.25 nMIn vitroLurbinectedin exhibits significant antitumor activity toward chemosensitive and chemoresistant CCC cells in vitro. Lurbinectedin plus SN-38 combination has strong synergistic effects on both the cisplatin-resistant and paclitaxel-resistant CCC cell lines.In vivoAn examination of mouse CCC cell xenografts reveals that lurbinectedin significantly inhibits tumor growth. Lurbinectedin plus SN-38 combination results in a significant synergistic effect. Everolimus significantly enhances the antitumor activity of lurbinectedin-based chemotherapies.Cell Research(from reference)Cell lines：The human ovarian CCC cell lines (RMG1, RMG2, KOC7C, HAC2) Concentrations：0.1 nM, 0.3 nM, 1 nM, 3 nM Incubation Time：48 h. Specification: 0.99 Molecular Formula: C41H44N4O10S Molecular Weight: 784.87 PubChem CID: 57327016 Isomeric SMILES: CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O